Eli Lilly and Company
NYSE:LLYDrug Manufacturers - General
-$10.54 today
- Market cap
- $1.30T
- Beta
- 0.52
- P/E (TTM)
- 39.0
- EPS (TTM)
- $28.26
- Dividend yield
- 0.59%
Volume 2.58M
Average 3.19M
LLY Sales of Investments
Cash received from selling or redeeming investments.
Eli Lilly and CompanyNYSE: LLY
Sales of Investments · Q2 FY2026 · quarter ended Jun 2026
Sales of investments outflow shrinks to $0
Q2 FY2026 sales of investments was $0, compared with $204.3M a year earlier. Trailing-twelve-month sales of investments was $688.1M. Over 3 fiscal years it compounded at +27.6% a year.
Context
- Sales of investments amounted to 1.5% of revenue in FY2025, up 0.3 pp from a year earlier.
- Sales of investments increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly sales of investments holds near $0 or moves back toward the trailing-twelve-month quarterly average of $172.03M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 964M USD
- Year-over-year change
- +84.5%
- 4-year CAGR
- +3.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 964M | +84.5% |
| FY2024 | 2024-12-31 | 522.5M | -25.4% |
| FY2023 | 2023-12-31 | 700.3M | +51.1% |
| FY2022 | 2022-12-31 | 463.6M | -45.3% |
| FY2021 | 2021-12-31 | 847.4M | — |
Sales of Investments vs competitors
How LLY compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +45.5% is the 2nd highest of 8, against a peer median of -70.2%.
- Sales of investments amounts to 0.9% of revenue for LLY, versus a peer median of 0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $12.53B USD | -38.1% | -20.7% | 19.7% | |
| LTM Jun 2026 | $1.92B USD | +72.7% | +32.5% | 2.9% | |
| LTM Sep 2026 | $1.41B USD | -18.6% | -65.8% | 1.4% | |
| LTM Jun 2026 | $1.19B USD | -70.2% | -61.9% | 2.1% | |
| LTM Jun 2026 | $688.1M USD | +45.5% | +27.6% | 0.9% | |
| LTM Jun 2026 | DKK 109M DKK | -99.4% | +17.1% | 0.0% | |
| LTM Jun 2026 | €90.99M EUR | — | — | 0.2% | |
| LTM Jun 2026 | $37M USD | -93.7% | -63.2% | 0.1% | |
| LTM Sep 2026 | $11.78M USD | -86.9% | +46.1% | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding LLY) | — | -70.2% | -20.7% | 0.2% | |
Competitors are the stored peer set for LLY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 5.58B | 6.24B | 5.24B | 10.59B | 20.64B |
| Depreciation & Amortization | 1.55B | 1.52B | 1.53B | 1.77B | 2B |
| Deferred Income Tax | (802.3M) | (2.19B) | (2.34B) | (2.68B) | (1.71B) |
| Stock-Based Compensation | 342.8M | 371.1M | 628.5M | 645.6M | 626M |
| Change in Working Capital | (1.01B) | (800K) | (3.06B) | (5.39B) | (8.09B) |
| Accounts Receivables | (1.28B) | (299.6M) | (2.45B) | (2.16B) | (7B) |
| Inventory | (235.9M) | (599.7M) | (1.43B) | (2.51B) | (4.67B) |
| Accounts Payables | (1.01B) | 1.33B | 4.27B | 2.61B | 10.19B |
| Other Working Capital | 1.52B | (433.2M) | (3.45B) | (3.33B) | (6.61B) |
| Other Non-Cash Items | 1.71B | 1.63B | 2.24B | 3.88B | 3.35B |
| Operating Cash Flow | 7.37B | 7.59B | 4.24B | 8.82B | 16.81B |
| Capital Expenditures | (1.98B) | (2.99B) | (7.39B) | (5.06B) | (7.84B) |
| Acquisitions (Net) | (747.4M) | (327.2M) | (1.04B) | (947.7M) | (661M) |
| Purchases of Investments | (1.01B) | (707.6M) | (829M) | (775.8M) | (645M) |
| Sales of Investments | 847.4M | 463.6M | 700.3M | 522.5M | 964M |
| Other Investing Activities | (644.3M) | (1.34B) | (2.53B) | 303.1M | (2.79B) |
| Investing Cash Flow | (2.87B) | (3.76B) | (7.15B) | (9.3B) | (10.97B) |
| Debt Repayment | 501.4M | (62M) | 8.65B | 8.9B | 8.05B |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (1.25B) | (1.5B) | (750M) | (2.5B) | (4.11B) |
| Dividends Paid | (3.09B) | (3.54B) | (4.07B) | (4.68B) | (5.38B) |
| Other Financing Activities | (295.9M) | (308.9M) | (335M) | (490.6M) | (772M) |
| Financing Cash Flow | (4.13B) | (5.41B) | 3.5B | 1.23B | (2.21B) |
| Effect of Forex Changes | (205.7M) | (167.6M) | 168.6M | (296.7M) | 372M |
| Net Change in Cash | 161.4M | (1.75B) | 751.6M | 449.8M | 4B |
| Free Cash Flow | 5.39B | 4.6B | (3.15B) | 3.76B | 8.97B |
Eli Lilly and Company
NYSE:LLY
Intrinsic Alpha fair value
Locked
Current Price
$1,382.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.